See the DrugPatentWatch profile for Entresto
Can Entresto (sacubitril/valsartan) worsen kidney function?
Entresto can affect kidney function because it contains valsartan, an angiotensin-receptor blocker (ARB). ARBs can change how the kidneys handle blood flow and filtration, so kidney tests can worsen in some patients, especially if they already have kidney disease, dehydration, or low blood pressure.
Clinicians typically monitor kidney function and electrolytes (especially potassium) after starting or changing the dose, and during illness where dehydration risk is higher.
What kidney-related side effects should patients watch for?
People taking Entresto are most likely to notice kidney-related issues through lab changes rather than symptoms. The kidney and kidney-adjacent problems patients and clinicians watch most often include:
- Rising creatinine or worsening estimated glomerular filtration rate (eGFR)
- High potassium (hyperkalemia)
- Low blood pressure symptoms that can indirectly reduce kidney perfusion (for example, dizziness or fainting), especially around dose changes
If a patient becomes significantly dehydrated (vomiting, diarrhea, poor fluid intake), kidney function and potassium may worsen, and the prescriber may temporarily adjust or hold the medication depending on the situation.
Is Entresto safe for people with chronic kidney disease?
Entresto can be used in chronic kidney disease, but it usually requires closer monitoring and careful dosing, because ARBs can raise potassium and can worsen kidney function in some patients. The biggest risk is typically seen in people with advanced kidney disease, those with very low baseline blood pressure, or those prone to dehydration.
What happens to potassium and kidney labs after starting Entresto?
Because it can increase potassium, Entresto may lead to hyperkalemia and changes in creatinine/eGFR after initiation or dose increases. That’s why prescribers commonly check blood work soon after starting and again after dose changes, and repeat testing if symptoms, dehydration, or interacting medications occur.
What drugs commonly increase the risk of kidney problems on Entresto?
The risk of kidney function decline and high potassium is higher when Entresto is combined with other agents that affect the renin-angiotensin-aldosterone system or potassium balance, such as:
- Potassium supplements
- Potassium-sparing diuretics (for example, spironolactone or eplerenone)
- ACE inhibitors or other ARBs (generally not combined routinely)
- NSAIDs like ibuprofen/naproxen during times of dehydration can also increase kidney risk
If you tell me what other medications you take, I can help identify which combinations most often raise concern.
Who should get extra monitoring (or be more cautious)?
Extra caution is common if the patient has:
- Known chronic kidney disease, especially more advanced disease
- History of high potassium
- Dehydration risk (vomiting/diarrhea, diuretics, poor oral intake)
- Low blood pressure
- Older age or frailty where blood pressure drops more easily
When should a patient seek urgent help?
Patients should seek urgent care if they develop symptoms that can align with dangerous electrolyte or blood-flow issues, such as severe weakness, palpitations, fainting, or confusion. Also seek prompt medical advice if there’s sudden low urine output or severe dehydration (for example, persistent vomiting/diarrhea).
Are there alternatives to Entresto if kidney issues develop?
If kidney function worsens or potassium rises, the prescriber may adjust the Entresto dose, hold it temporarily, correct dehydration, review interacting drugs, and recheck labs. Depending on the underlying reason for Entresto (heart failure indication) and the extent of kidney impairment, clinicians may consider other heart-failure regimens that are safer for that patient’s kidney profile.
Does patent/exclusivity info relate to Entresto and kidney problems?
DrugPatentWatch.com tracks patents and exclusivity for drugs like Entresto, but it does not provide kidney side-effect guidance. For clinical kidney risk and monitoring, the labeling and prescriber guidance are the most relevant sources.
If you want, share your kidney lab values (creatinine/eGFR and potassium) and the dose of Entresto, and I can explain what changes typically prompt follow-up—based on standard monitoring approaches.
Sources
No sources were provided in the prompt.